CliffBio
small molecule

NATESTO

TESTOSTERONE

Loss of exclusivityMarch 2034latest FDA-listed patent expiry
CompanyAcerus Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameNATESTO
Active ingredientTESTOSTERONE
Strength5.5MG/0.122GM ACTUATION
Dosage formGEL, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalMay 2014
Marketing statusRX

Listed patents

PatentExpiresType
11744838March 2034use U-4367
11090312March 2034use U-1616

More from Acerus Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NATESTO patent cliff — loss of exclusivity March 2034 | CliffBio